Colorectal, Cancer Clinical Trials
Colorectal, Cancer Trials at a Glance
10 actively recruiting trials for colorectal, cancer are listed on ClinicalTrialsFinder across 6 cities in 5 countries. The largest study group is Not Applicable with 5 trials, with the heaviest enrollment activity in Shanghai, Bethesda, and Chapel Hill. Lead sponsors running colorectal, cancer studies include European Institute of Oncology, Fudan University, and Beijing Friendship Hospital.
Top cities for colorectal, cancer trials
Treatments under study
Understanding Colorectal Cancer Clinical Trials
Immunotherapy has transformed outcomes for colorectal cancer patients whose tumors are microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR), with pembrolizumab (Keytruda) now approved as a first-line treatment in this population based on landmark trial results. For the broader population of microsatellite stable (MSS) colorectal cancers, trials are urgently testing strategies to unlock immunotherapy's potential, alongside new targeted therapies against KRAS G12C, BRAF V600E, and HER2. Clinical trials are also pioneering liquid biopsy technology for early detection and monitoring of treatment response.
Why Consider a Clinical Trial?
Frequently Asked Questions
Common questions about Colorectal, Cancer clinical trials
MSI-H (microsatellite instability-high) or dMMR (mismatch repair deficient) tumors respond well to immunotherapy. If your tumor has this profile, you have access to immunotherapy as standard treatment and may also qualify for trials testing novel immunotherapy combinations. This result also has implications for hereditary cancer screening (Lynch syndrome).
Yes. Liver metastases are common in colorectal cancer, and many trials specifically address this scenario. Options include trials of hepatic arterial infusion chemotherapy, combination targeted therapy, immunotherapy approaches, and novel radiation techniques. Some trials also study whether select liver metastases can be safely resected after tumor shrinkage with new drug combinations.
A liquid biopsy is a blood test that detects fragments of tumor DNA circulating in your bloodstream. In colorectal cancer trials, it is used to monitor treatment response, detect recurrence before it appears on scans, and guide treatment decisions — such as whether post-surgical chemotherapy is needed. It is minimally invasive and can be repeated over time.
Yes. Many colorectal cancer trials are designed for patients who have progressed through standard chemotherapy regimens. Late-line trials test novel mechanisms of action that work differently from conventional chemotherapy. Your prior treatment history helps determine which trials best match your situation.
Showing 1–10 of 10 trials